Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-007
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SC-007 is an investigational antibody-drug conjugate (ADC) developed by AbbVie for the treatment of advanced cancers, specifically colorectal cancer and gastric (stomach) cancer. The drug consists of a humanized IgG1 monoclonal antibody targeting a tumor-associated antigen (P41273, also known as TNFL9_HUMAN), conjugated to a pyrrolobenzodiazepine (PBD) cytotoxic payload. Upon intravenous administration, SC-007 binds to the tumor-associated antigen on cancer cells; after internalization, it releases the PBD toxin inside the cell, leading to targeted cell death. The development program was discontinued in Phase 1 due to dose-limiting toxicities and failure to meet primary endpoints in early clinical trials[2][3][4][5].
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on SC-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-007.